

## **Akzo Nobel secures new financial arrangement**

**Arnhem, the Netherlands, May 11, 2006 — Akzo Nobel has announced the signing today of a new seven-year EUR 1.5 billion multi-currency revolving credit facility.**

The new financial arrangement replaces a similar EUR 1.5 billion credit facility which was due to expire in November 2008.

The new facility takes advantage of favorable conditions in credit markets. It will, like the previous facility, be used as liquidity backup for Akzo Nobel's commercial paper programs and for general funding purposes.

Akzo Nobel has never drawn on its previous facility.

- - -

### **Note for the editor**

Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and the FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 61,500 people and conduct our activities in four segments – human and animal health, coatings and chemicals – subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the second quarter will be published on July 20, 2006.

Internet: [www.akzonobel.com](http://www.akzonobel.com)

### **Not for publication – for more information**

Akzo Nobel nv  
Corporate Media Relations, tel. +31 26 366 43 43  
Contact: Tim van der Zanden

### **Safe Harbor Statement\***

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website [www.akzonobel.com](http://www.akzonobel.com). The 2005 Annual Report on Form 20-F will be available at the end of the second quarter of 2006.

\* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.